2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1002

Global Transcriptome Analysis in Osteoarthritic Cartilage Reveals Significant Differential Gene Expression and Associations with Histologic Disease Progression
Abstract Number: 919

Glucocorticoid Exposure and Fracture Risk in a Large Cohort of Commercially-Insured Rheumatoid Arthritis Patients Under Age 65
Abstract Number: 2315

Glucocorticoid Induced Osteoporosis Screening and Treatment in a Cohort of Male Patients with Underlying Rheumatologic Diagnosis in a Tertiary Care Setting
Abstract Number: 2360

Glucocorticoids and Vascular Function in Arthritis: Benefic or Deleterious Effects? Study in Rat
Abstract Number: 463

Golimumab 5-Year Safety: an Analysis of Pooled Data from the Long Term Extensions of Randomized, Double-Blind, Placebo-Controlled Studies in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
Abstract Number: 1250

Golimumab As an Alternative Therapy in Patients with Uveitis Refractory to Other Anti-TNFα Drugs. Multicenter Study of 29 Cases
Abstract Number: 2512

Golimumab Therapy Retention Rates in Patients with Rheumatoid Arthritis and Seronegative Spondyloarthritis: Data from the Italian Lorhen Registry
Abstract Number: 854

Golimumab Versus Pamidronate for the Treatment of Axial Spondyloarthropathy (SpA): A 48-Week Randomized Controlled Trial
Abstract Number: 2510

Good Response to Methotrexate (MTX) and/or MTX Plus Adallimumab (ADA): 3 Yrs Study Results in Patients with Rheumatoid Arthritis (RA)
Abstract Number: 827

Gout and the Risk of Alzheimer’s Disease: A Population-Based Cohort Study
Abstract Number: 1872

Gout in Older Adult
Abstract Number: 164

Gouty Patients with History of Adverse Reaction to Allopurinol Are Not at Higher Risk of Reaction to Febuxostat
Abstract Number: 1767

Granulomatosis with Polyangiitis (Wegener’s) According to Geographic Origin and Ethnicity: Clinical-Biological Presentation and Outcome
Abstract Number: 1774

Granulomatosis with Polyangiitis (Wegener’s): Endoscopic Management of Tracheobronchial Stenosis – Results from a Multicenter Experience in 47 Patients
Abstract Number: 1864

Granulomatosis with Polyangiitis or Microscopic Polyangiitis: Long-Term Outcomes of the Prospective Wegent Trial Comparing Azathioprine Vs Methotrexate for Remission-Maintenance in 126 Patients

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].